

Amendments to the Claims:

Please cancel claims 1-6, 8-10, and 12; please amend claims 7, 13-14, and 16 as summarized below.

Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (canceled)

Claim 5. (canceled)

Claim 6. (canceled)

Claim ¹~~7~~ (amended) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising ^{the protein of} ~~an amino acid substitution in~~ SEQ ID NO:1, ^{with the exception that the residue of} ~~selected from the group~~ position 218 ^{is a} ~~consisting of:~~ substitution

- a. Arg at position 218 is replaced by Gln
- b. Arg at position 218 is replaced by Glu;
- ~~c. Thr at position 216 is replaced by Pro;~~
- ~~d. Arg at position 218 is replaced by Ala;~~
- ~~e. Arg at position 218 is replaced by Gly;~~
- ~~f. Arg at position 218 is replaced by Ser;~~
- ~~g. Arg at position 218 is replaced by Val;~~
- ~~h. Arg at position 218 is replaced by Tyr; and~~
- ~~i. Arg at position 218 is replaced by Asn; and~~
- ~~j. Pro at position 217 is replaced by Tyr.~~

Claim 8. (canceled)

Claim 9. (canceled)

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (canceled)

Claim ²~~13~~ (amended) A FLINT analog ~~as in Claim 1~~ wherein Thr at position 216 of SEQ ID NO:1 is replaced by Pro, and Arg at position 218 is replaced by Gln.

Claim ³~~14~~ (amended) A method to treat or prevent a disease or condition in a mammal comprising the administration of a therapeutically effective amount of a protease resistant FLINT analog of claim ¹~~2~~ ^{or claim} ²~~13~~.

Serial No. 09/936,019

Reply to Office Action of Dec. 18, 2003

⁴
Claim ~~15~~ (original) A method as in Claim ³~~14~~ wherein said disease or condition is acute lung injury, acute respiratory distress syndrome, or ulcerative colitis.

Claim ~~16~~ ⁵ (amended) A pharmaceutical formulation comprising as an active ingredient a protease resistant FLINT analog of claim 2 ~~or claim 13~~ ² associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

Claim 17-20 (canceled)

Claim ~~21~~ ⁶ (original) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising the amino acid sequence of SEQ ID NO:1, wherein Arg at position 218 is substituted by Gln.

Claims 22-23 (canceled)